Aliskiren is a renin inhibitor indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. MedsAcross supplies Aliskiren for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Tekturna is a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Source: US FDA prescribing information
Renin is secreted by the kidney in response to decreases in blood volume and renal perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system. This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS).
Source: US FDA prescribing information
Starting dose (adults and pediatric patients): 150 mg once daily with a routine pattern with regard to meals. If blood pressure remains uncontrolled titrate up to 300 mg daily. Majority of effect of given dose attained in 2 weeks.
Source: US FDA prescribing information
Do not use Tekturna with ARBs or ACEIs in patients with diabetes. Tekturna is contraindicated in patients with known hypersensitivity to any of the components. Tekturna is contraindicated in pediatric patients less than 2 years of age because of the risk of high aliskiren exposures identified in juvenile animals due to immaturity of transporters and metabolic enzymes. Do not use with angiotensin receptor blockers (ARBs) or angiotensin- converting enzyme inhibitors (ACEIs) in patients with diabetes. Hypersensitivity to any of the components. Tekturna is contraindicated in pediatric patients less than 2 years of age.
Source: US FDA prescribing information
Boxed warning (fetal toxicity): When pregnancy is detected, discontinue Tekturna as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Avoid concomitant use with ARBs or ACEIs particularly in patients with renal impairment [creatinine clearance (CrCl) <60 mL/min]. Anaphylactic Reactions and Head and Neck Angioedema. Hypotension: Correct imbalances in volume and/or salt depleted patients. Impaired Renal Function: Monitor serum creatinine periodically. Hyperkalemia: Monitor potassium levels periodically.
Source: US FDA prescribing information
Most common adverse reaction: diarrhea (incidence 2.3%).
Source: US FDA prescribing information
Cyclosporine: Avoid coadministration of cyclosporine with aliskiren. Itraconazole: Avoid coadministration of itraconazole with aliskiren. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving aliskiren and NSAID therapy. The antihypertensive effect of aliskiren may be attenuated by NSAIDs.
Source: US FDA prescribing information
Store at 20°C to 25ºC (68°F to 77ºF), excursions permitted to 15ºC to 30ºC (59 ºF to 86ºF). Protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
4 presentations of Aliskiren, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Aliskiren 150 mg tabletOralGeneric name | — | US FDA | Available on request |
| Aliskiren 300 mg tabletOralGeneric name | — | US FDA | Available on request |
| Tekturna 150 mg tabletOral | Lxo | US FDA | Available on request |
| Tekturna 300 mg tabletOral | Lxo | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Aliskiren in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 4 presentations of Aliskiren and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Aliskiren, including Tekturna.
Yes. The US FDA first approved Aliskiren on 5 March 2007, according to Drugs@FDA.
Yes. Aliskiren has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Aliskiren is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Aliskiren is classified under ATC code C09XA02 (Aliskiren).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.